Cancer Biology and Therapeutics

Companion Diagnostics in oncology

Submit Abstract Register Now

Companion Diagnostics market has been segmented geographically into North America, Europe, Asia Pacific and LAMEA. North America has the major market share of 43.97% followed by Europe, which accounted for about 38% of the overall CD market in 2013. North America and Europe together accounted for over 82% in the global CD market in 2013 and they would continue to be the major markets through 2020. This is mainly due to the increasing incidence of cancer and other diseases and higher health care awareness in these regions.Companion diagnostics is segmented on the basis of its use for indications such as oncology, cardiovascular conditions, central nervous system indications, inflammation and virology. Oncology is the highest revenue generating segment, as majority of the companion diagnostics have been developed for detection of various cancer biomarkers. The key driver for this market is an increase in research and development of targeted drugs, which require a corresponding companion diagnostic.This Session Includes Cancer screening and early detection & prevention, Molecular diagnostics, Digital cancer pathology and imaging, Personalized genomics and clinical biomarkers, Diffuse optical imaging, Magnetic resonance imaging, Positron emission tomography, Computed tomography, Structural and functional imaging, Radioactive compounds in Neuroimaging, Biomarker Discovery.For More Information please, CLICK HERE